WallStSmart

Lite Strategy, Inc. (LITS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target

Lite Strategy, Inc. stock (LITS) is currently trading at $1.20. Lite Strategy, Inc. PS ratio (Price-to-Sales) is 0.31. WallStSmart rates LITS as Sell.

  • LITS PE ratio analysis and historical PE chart
  • LITS PS ratio (Price-to-Sales) history and trend
  • LITS intrinsic value — DCF, Graham Number, EPV models
  • LITS stock price prediction 2025 2026 2027 2028 2029 2030
  • LITS fair value vs current price
  • LITS insider transactions and insider buying
  • Is LITS undervalued or overvalued?
  • Lite Strategy, Inc. financial analysis — revenue, earnings, cash flow
  • LITS Piotroski F-Score and Altman Z-Score
  • LITS analyst price target and Smart Rating
LITS

Lite Strategy, Inc.

NASDAQHEALTHCARE
$1.20
$0.02 (1.69%)
52W$0.95
$8.25

📊 No data available

Try selecting a different time range

WallStSmart

Smart Analysis

Lite Strategy, Inc. (LITS) · 6 metrics scored

Smart Score

34
out of 100
Grade: F
Avoid
Investment Rating

Category Performance

WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.

Investment Thesis

Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.

Lite Strategy, Inc. (LITS) Key Strengths (2)

Avg Score: 10.0/10
Price/SalesValuation
0.3110/10

Paying less than $1 for every $1 of annual revenue

Price/BookValuation
0.5310/10

Trading below book value, meaning the market prices it less than net assets

Supporting Valuation Data

Forward P/E
4.621
Attractive
Price/Sales (TTM)
0.313
Undervalued
EV/Revenue
0.812
Undervalued

Lite Strategy, Inc. (LITS) Areas to Watch (4)

Avg Score: 2.8/10
Return on EquityProfitability
-76.40%0/10

Company is destroying shareholder value

Market CapQuality
$43M3/10

Micro-cap company with very limited liquidity and high volatility

PEG RatioValuation
2.224/10

Paying a premium for growth, expensive relative to earnings expansion

Institutional Own.Quality
22.75%4/10

Low institutional interest, mostly retail-driven

Lite Strategy, Inc. (LITS) Detailed Analysis Report

Overall Assessment

This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.

The Bull Case

The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.31), Price/Book (0.53) suggest the stock is attractively priced.

The Bear Case

The primary concerns are Return on Equity, Market Cap, PEG Ratio. Some valuation metrics including PEG Ratio (2.22) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -76.40%.

Key Dynamics to Monitor

Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -76.40% needing improvement to support the investment thesis. Third, top-line growth trajectory.

Risk Considerations

Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.

Bottom Line

Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.

Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.

LITS Price-to-Sales(PS) Ratio Chart

Historical valuation based on market cap ÷ trailing 12-month revenue

LITS's Price-to-Sales ratio of 0.31x trades at a deep discount to its historical average of 1.07x (15th percentile). The current valuation is 90% below its historical high of 3.09x set in Sep 2021, and 42% above its historical low of 0.22x in Dec 2022.

Compare LITS with Competitors

Top BIOTECHNOLOGY stocks by market cap

Compare any two stocks →

WallStSmart Analysis Synopsis

Data-driven financial summary for Lite Strategy, Inc. (LITS) · HEALTHCAREBIOTECHNOLOGY

The Big Picture

Lite Strategy, Inc. operates as a stable business with moderate growth and solid fundamentals.

Key Findings

Negative Free Cash Flow

Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.

What to Watch Next

Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Lite Strategy, Inc..

Bottom Line

Lite Strategy, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.

This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Insider Transactions

Total Buys
0
Total Sells
0

Data sourced from SEC Form 4 filings

Last updated: 10:06:48 AM

About Lite Strategy, Inc.(LITS)

Exchange

NASDAQ

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Country

USA

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company is headquartered in San Diego, California.